CEVEC Pharmaceuticals entered into an agreement with UCB covering the evaluation and use of CEVEC’s proprietary ELEVECTA® technology for the R&D and manufacturing of Adeno-Associated Virus (AAV) vectors for gene therapy applications.

CEVEC granted UCB non-exclusive rights for R&D using ELEVECTA producer cell lines for specific transgenes selected by UCB. The agreement also grants UCB options to obtain licenses for use of the ELEVECTA producer cell lines in commercial manufacturing of potential AAV gene therapy products, and for the internal use of ELEVECTA at UCB to generate new producer cell lines.

CEVEC is eligible for license fees, clinical, and regulatory milestone payments, as well as royalties on potential future net sales.

“We are very pleased to have UCB embarking on the ELEVECTA technology enabling them to use the platform for scalable, robust and efficient manufacturing of gene therapy vectors,” says Nicole Faust, PhD, CEO of CEVEC. “This license agreement represents a further step towards establishing ELEVECTA as the future AAV manufacturing standard. With more and more gene therapies in development, we see an increasing need in the industry for scalable manufacturing technologies to enable production of AAV vectors at large scale.”

Previous articleGenentech, Adaptimmune Launch Up to $3B Cancer T Cell Therapy Collaboration
Next articleGenomic Analysis of Lung Cancer in Never Smokers Identifies Three Molecular Subtypes